SCHEMBL25455629

SCHEMBL25455629

CCC(C)(CC)c1cnc(-c2ccc(C)cc2)cc1C(C)(CC)CC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ METAP2 P50579 1/20 0.35
▸ METAP1 P53582 1/20 0.35
▸ KDM1A O60341 2/20 0.35
▸ CCR1 P32246 1/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ADORA3 P0DMS8 2/20 0.34
▸ SREBF2 Q12772 2/20 0.34
▸ SREBF1 P36956 1/20 0.34
▸ AURKA O14965 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24066428 0.89 LDHA (0.36) CYP11B1CYP11B2METAP2METAP1KDM1A
SCHEMBL22674922 0.85 LDHA (0.41) CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2
SCHEMBL23561573 0.84 CYP11B1 (0.35) CYP11B1CYP11B2METAP2METAP1KDM1A
SCHEMBL22675050 0.80 METAP2 (0.39) CYP11B1CYP11B2METAP2METAP1KDM1A
SCHEMBL22079793 0.79 LDHA (0.36) CYP11B1CYP11B2METAP2METAP1KDM1A
SCHEMBL26000216 0.78 LDHA (0.38) CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2
SCHEMBL25796037 0.77 CYP11B1 (0.37) CYP11B1CYP11B2METAP2METAP1KDM1A
SCHEMBL25884943 0.76 LDHA (0.45) CYP11B1CYP11B2HDAC6NPC1RAB9A
SCHEMBL26290575 0.76 LDHA (0.49) CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2
SCHEMBL23561619 0.75 KDM1A (0.42) METAP2METAP1KDM1ACCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348508-A1 METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 — — US disclosed
US-20230143449-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143449-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, OXER1 CYP11B1 1323/4885CYP11B2 1428/4885METAP2 4573/4885
US-20230348508-A1 METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT TRPM5, TRPM6, TRPM2 CYP11B1 4768/4885CYP11B2 4669/4885METAP2 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback